Use this URL to cite or link to this record in EThOS:
Title: CD40 antibodies for the treatment of human malignancy
Author: Harvey, Melanie Louise.
ISNI:       0000 0001 3542 7555
Awarding Body: University of Southampton
Current Institution: University of Southampton
Date of Award: 2002
Availability of Full Text:
Full text unavailable from EThOS.
Please contact the current institution’s library for further details.
CD40 is an important antigen involved in immune regulation and anti-CD40 antibody therapies against human CD40 expressing tumours may be particularly advantageous. The antibody could induce tumour response in two ways. Firstly it might have a direct anti-tumour effect and secondly it could 'boost' the immune system to provide a heightened immune response that evades tumour tolerance. This project has explored the effects of CD40 ligation of a variety of CD40 expressing tumours including transformed human B cell lines (RL and Daudi), human epithelial cell lines (MG79 [ovarian] and Caski [cervical]) and primary human B cell non-Hodgkin's lymphomas obtained, with consent, from patients undergoing excision lymph node biopsy or splenectomy. The ligation of CD40, on transformed human B cell lines, using chinese hamster ovary cells transfected to express human CD40L and human soluble CD40L has shown significant cellular growth inhibition (p
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (M.D.) Qualification Level: Doctoral
EThOS ID:  DOI: Not available
Keywords: Lymphoma, Tumours,